Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00583206

Muscle Atrophy in Sepsis

Biochemical Pathways to Skeletal Muscle Atrophy in Human Sepsis

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Gregory A. Schmidt · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Severe sepsis will provoke signals leading to muscle atrophy and weakness. Electrical stimulation will reduce the impact of sepsis.

Detailed description

Hypothesis 1: Severe sepsis will be associated with downregulation of anabolic signaling molecules and genes, upregulation of catabolic signaling molecules and genes, and the development of histologic and electrophysiologic abnormalities within skeletal muscle. Hypothesis 2: Electrical stimulation will improve muscle strength in patients with sepsis. Hypothesis 3: Electrical stimulation will be associated with upregulation of anabolic signaling molecules and genes, downregulation of catabolic signaling molecules and genes, and improvement of histologic and electrophysiologic parameters within skeletal muscle of patients with sepsis. Hypothesis 4: The ratio of catabolic:anabolic gene expression on Day 3 will be positively correlated with the severity of clinical weakness on Day 7

Conditions

Timeline

Start date
2007-12-01
Primary completion
2009-12-01
Completion
2009-12-01
First posted
2007-12-31
Last updated
2017-02-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00583206. Inclusion in this directory is not an endorsement.